Medical Condition News

RSS

MD Anderson introduces Moon Shots Program to reduce cancer deaths

The University of Texas MD Anderson Cancer Center announces the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.

21 Sep 2012

Thyroid cancer among people with low SES is diagnosed at a more advanced stage

Thyroid cancer among people with lower socioeconomic status is diagnosed at a more advanced stage, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

21 Sep 2012

Loss of IGSF1 gene function causes central hypothyroidism

Loss of function in the X-linked immunoglobulin superfamily member 1 (IGSF1) gene causes central hypothyroidism, testicular enlargement, and variable prolactin deficiency, according to data presented at the 82nd Annual Meeting of the American Thyroid Association in Québec City, Québec, Canada.

21 Sep 2012

Caltech biologists gain new insight into migrating cells

At any given moment, millions of cells are on the move in the human body, typically on their way to aid in immune response, make repairs, or provide some other benefit to the structures around them. When the migration process goes wrong, however, the results can include tumor formation and metastatic cancer. Little has been known about how cell migration actually works, but now, with the help of some tiny worms, researchers at the California Institute of Technology (Caltech) have gained new insight into this highly complex task.

21 Sep 2012

ChromaDex announces findings from pTeroPure Phase 2/3 trial on high blood pressure

ChromaDex Corporation announced today findings from a Phase 2/3 trial at the University of Mississippi Medical Center showing its patented nutritional ingredient pTeroPure (pterostilbene) significantly reduced blood pressure in adults.

21 Sep 2012

Iron transport may contribute to diabetes

Scientists have been trying to explain the causes of diabetes for many years. Researchers at the University of Copenhagen and Novo Nordisk A/S have now shown that the increased activity of one particular iron-transport protein destroys insulin-producing beta cells. In addition, the new research shows that mice without this iron transporter are protected against developing diabetes.

21 Sep 2012

Study identifies factors that contribute to solid stress within tumors

It's a high-pressure environment within solid tumors. Abnormal blood and lymphatic vessels cause fluids to accumulate, and the uncontrolled proliferation of cancer cells within limited space leads to the buildup of what is called solid stress.

21 Sep 2012

Mathematical modeling can help treat several diseases

Mathematical modeling being tested by researchers at the School of Science at Indiana University-Purdue University Indianapolis (IUPUI) and the IU School of Medicine has the potential to impact the knowledge and treatment of several diseases that continue to challenge scientists across the world.

21 Sep 2012

Research focuses on HER2 cancers

As scientists continue to map breast cancer's complex genetic makeup, research at Michigan State University could lead to better diagnoses and new treatment targets.

21 Sep 2012

Childhood emotional neglect may increase risk of stroke in later adulthood

The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.

21 Sep 2012

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today reported milestone achievements advancing BiovaxID, Biovest's personalized cancer vaccine for the treatment of non-Hodgkin's lymphoma, including a recently conducted regulatory meeting with the European Medicines Agency (EMA) and the appointment of a key contributor to the Human Genome Project to its Scientific Advisory Board.

21 Sep 2012

Study of spinal injury data may help surgeons treat injured soldiers or civilians

Spinal injuries are among the most disabling conditions affecting wounded members of the U.S. military. Yet until recently, the nature of those injuries had not been adequately explored.

21 Sep 2012

First extensive analysis of Allen Human Brain Atlas

Scientists at the Allen Institute for Brain Science reported in the latest issue of the journal Nature that human brains share a consistent genetic blueprint and possess enormous biochemical complexity. The findings stem from the first deep and large-scale analysis of the vast data set publicly available in the Allen Human Brain Atlas.

21 Sep 2012

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Acton Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the sNDA (Supplemental New Drug Application) for AEROSPAN (flunisolide HFA, 80 mcg) Inhalation Aerosol, a hydrofluoroalkane (HFA) orally inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy in adult and pediatric patients 6 years of age and older.

21 Sep 2012

Data from Navidea’s Lymphoseek Phase 3 studies on solid tumors to be presented at ESSO

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.

21 Sep 2012

Itrim programme effectively reduces weight among obese people

Anyone who wants to lose weight has a wide variety of diets to choose from, but knowledge of what works is often poor. Researchers at Karolinska Institutet and Uppsala University have now evaluated a Swedish commercial weight loss programme called Itrim, and found it to be effective. After one year, participants had lost 11 kg on average.

21 Sep 2012

St. Jude Medical’s Eon family of neurostimulators receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.

21 Sep 2012

Newly formed emotional memories can be erased from the human brain

Newly formed emotional memories can be erased from the human brain. This is shown by researchers from Uppsala University in a new study now being published by the academic journal Science. The findings may represent a breakthrough in research on memory and fear.

21 Sep 2012

Positive results from Galleon GAL-021 second Phase I study on respiratory depression

Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing control disorders, today announced that results from a second Phase I clinical study of its investigational drug GAL-021 confirmed previous findings that the drug has dose-dependent effects on respiration.

21 Sep 2012

Hypertonic solution effective in reducing inflammation

Research carried out at The University of Manchester has found further evidence that a simple solution, which is already used in IV drips, is an effective treatment for reducing inflammation.

From The University of Manchester 21 Sep 2012